Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
A 1-year randomized Phase II core trial was conducted to investigate the efficacy of
deferasirox in regularly transfused patients with β-thalassemia and other rare chronic anemia
2 years of age and older. Patients who successfully completed the main trial may continue in
the extension trial to receive chelation therapy with deferasirox for up to 3 years.
Extension was prolonged to 4 years.
The objective of this study is to assess the long-term safety and efficacy of deferasirox in
these patient groups.